9454 related articles for article (PubMed ID: 19018742)
1. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
4. [Electrolyte and acid-base balance disorders in advanced chronic kidney disease].
Alcázar Arroyo R
Nefrologia; 2008; 28 Suppl 3():87-93. PubMed ID: 19018744
[TBL] [Abstract][Full Text] [Related]
5. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
[TBL] [Abstract][Full Text] [Related]
6. Renal osteodystrophy in dialysis patients: diagnosis and treatment.
Fournier A; Oprisiu R; Hottelart C; Yverneau PH; Ghazali A; Atik A; Hedri H; Said S; Sechet A; Rasolombololona M; Abighanem O; Sarraj A; El Esper N; Moriniere P; Boudailliez B; Westeel PF; Achard JM; Pruna A
Artif Organs; 1998 Jul; 22(7):530-57. PubMed ID: 9684690
[TBL] [Abstract][Full Text] [Related]
7. [Renal osteodystrophy (3); its treatment in dialysis patients].
Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
[TBL] [Abstract][Full Text] [Related]
8. Interventions for metabolic bone disease in children with chronic kidney disease.
Hahn D; Hodson EM; Craig JC
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD008327. PubMed ID: 26561037
[TBL] [Abstract][Full Text] [Related]
9. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
Martin KJ; González EA
Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
[TBL] [Abstract][Full Text] [Related]
10. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
Shahapuni I; Mansour J; Harbouche L; Maouad B; Benyahia M; Rahmouni K; Oprisiu R; Bonne JF; Monge M; El Esper N; Presne C; Moriniere P; Choukroun G; Fournier A
Semin Dial; 2005; 18(3):226-38. PubMed ID: 15934970
[TBL] [Abstract][Full Text] [Related]
11. Use of alkaline calcium salts as phosphate binder in uremic patients.
Fournier A; Morinière P; Ben Hamida F; el Esjer N; Shenovda M; Ghazali A; Bouzernidj M; Achard JM; Westeel PF
Kidney Int Suppl; 1992 Oct; 38():S50-61. PubMed ID: 1405382
[TBL] [Abstract][Full Text] [Related]
12. [Renal osteodystrophy Guidelines].
Messa P;
G Ital Nefrol; 2003; 20 Suppl 24():S83-95. PubMed ID: 14666505
[TBL] [Abstract][Full Text] [Related]
13. Renal ostodystrophy during the developing stage of maintenance dialysis in Transylvania. Early development of periarticular calcifications and beta 2 microglobulin amyloidosis in spite of a relatively good prevention of secondary hyperparathyroidism.
Oprisiu R; Bolosiu H; Boca I; Theodoru C; Elefterescu R; Brazier M; el Esper I; Leflon P; Ledeme C; Fournier A; Heinze V
Ann Med Interne (Paris); 1998 Mar; 149(2):67-75. PubMed ID: 11490527
[TBL] [Abstract][Full Text] [Related]
14. Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: effects on bone mineral metabolism. Collaborators of the Multicenter Study Group.
Weinreich T; Ritz E; Passlick-Deetjen J
Perit Dial Int; 1996; 16(3):260-8. PubMed ID: 8761540
[TBL] [Abstract][Full Text] [Related]
15. [Diagnosis and treatment of osteoporosis in patients with chronic kidney disease : Joint guidelines of the Austrian Society for Bone and Mineral Research (ÖGKM), the Austrian Society of Physical and Rehabilitation Medicine (ÖGPMR) and the Austrian Society of Nephrology (ÖGN)].
Cejka D; Wakolbinger-Habel R; Zitt E; Fahrleitner-Pammer A; Amrein K; Dimai HP; Muschitz C
Wien Med Wochenschr; 2023 Oct; 173(13-14):299-318. PubMed ID: 36542221
[TBL] [Abstract][Full Text] [Related]
16. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.
Craver L; Marco MP; Martínez I; Rue M; Borràs M; Martín ML; Sarró F; Valdivielso JM; Fernández E
Nephrol Dial Transplant; 2007 Apr; 22(4):1171-6. PubMed ID: 17205962
[TBL] [Abstract][Full Text] [Related]
17. [Renal osteodystrophy (2): its treatment in renal insufficiency before dialysis].
Hottelart C; Bako G; Oprisiu R; Georgita A; Presne C; Sarraj A; Morinière P; el Esper N; Fournier A
Nephrologie; 2000; 21(6):275-82. PubMed ID: 11117106
[TBL] [Abstract][Full Text] [Related]
18. Management of hyperphosphataemia in dialysis patients: role of phosphate binders in the elderly.
Lorenzo Sellares V; Torres Ramírez A
Drugs Aging; 2004; 21(3):153-65. PubMed ID: 14979734
[TBL] [Abstract][Full Text] [Related]
19. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.
Block GA; Zeig S; Sugihara J; Chertow GM; Chi EM; Turner SA; Bushinsky DA;
Nephrol Dial Transplant; 2008 Jul; 23(7):2311-8. PubMed ID: 18310602
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of vitamin d testing: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(2):1-93. PubMed ID: 23074397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
